Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Silymarin vs silymarin + biphenyl dimethyl dicarboxylate + ursodeoxycholic acid in MetALD
KCT0012071Phase 4Not yet recruiting
- Sponsor
- Bukwang Pharmaceutical
- Start
- Aug 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of silymarin, bifendate and ursodeoxycholic acid in alcoholic liver disease (ALD), metabolic dysfunction-associated steatotic liver disease (MASLD) and cardiometabolic risk (CMR) (2 arms), sponsored by Bukwang Pharmaceutical. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
silymarinbifendateursodeoxycholic acid
03
Conditions
alcoholic liver disease (ALD)metabolic dysfunction-associated steatotic liver disease (MASLD)cardiometabolic risk (CMR)
Beyond the preview
Go deeper on KCT0012071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0012071.